公开(公告)号：US12186325B2

公开(公告)日：2025-01-07

申请号：US17290038

申请日：2019-10-30

Applicant: SEROJAC PME Handels GmbH

Inventor： Daniel Drai

IPC: A61K31/55 ,  A61K31/475 ,  A61P15/00

Abstract: A pharmaceutical composition may include clomipramine or a pharmaceutically acceptable salt form thereof and yohimbine or a pharmaceutically acceptable salt form thereof and may be used in the treatment and prevention of premature ejaculation. The composition may contain, for example, 5 to 150 mg clomipramine, and/or, for example, 5 to 150 mg yohimbine.

公开(公告)号：US20250000833A1

公开(公告)日：2025-01-02

申请号：US18885140

申请日：2024-09-13

Applicant: Fera Diagnostics and Biologicals Corp.

Inventor： Rodrigo Carvalho Bicalho ,  Marjory Xavier Rodrigues ,  Leonardo Bringhenti

IPC: A61K31/201 ,  A61K31/202 ,  A61K35/06 ,  A61K45/06 ,  A61P1/12 ,  A61P3/04 ,  A61P15/00 ,  A61P25/00

Abstract: A composition comprising a mixture of fatty acids such as linoleic, oleic, and palmitic acids or derivatives thereof derived from secretions of mammalian mammary glands. This composition can be utilized to decrease stress, anxiety, and aggressiveness in mammals.

公开(公告)号：US20240415862A1

公开(公告)日：2024-12-19

申请号：US18703429

申请日：2022-10-12

Applicant: ELYSIUM HEALTH INC. ,  UNIVERSITY OF SOUTHERN ALABAMA

Inventor： Ryan DELLINGER ,  Marie MIGAUD

IPC: A61K31/706 ,  A61K31/09 ,  A61K31/455 ,  A61P15/00

Abstract: The present application provides methods for reducing the severity or frequency of menopausal symptoms by administering (a) a therapeutically effective amount of nicotinamide riboside, nicotinamide mononucleotide, nicotinamide, nicotinic acid, the reduced form of nicotinamide riboside (NRH), or a mixture thereof, and (b) a therapeutically effective amount of pterostilbene. The compositions can be administered orally or via other suitable administration routes.

公开(公告)号：US20240350521A1

公开(公告)日：2024-10-24

申请号：US18641154

申请日：2024-04-19

Applicant: TAIPEI MEDICAL UNIVERSITY

Inventor： Yang-Ching CHEN

IPC: A61K31/704 ,  A61P5/24 ,  A61P15/00

CPC classification number: A61K31/704 ,  A61P5/24 ,  A61P15/00

Abstract: Provided is a method for preventing or treating precocious puberty in a subject in need thereof. The method includes administering to the subject an effective amount of glycyrrhizin or a salt or derivative thereof and an acceptable excipient thereof. Also provided is a composition for use in preventing or treating precocious puberty in a subject in need thereof.

公开(公告)号：US12109272B2

公开(公告)日：2024-10-08

申请号：US17902701

申请日：2022-09-02

Applicant: Corcept Therapeutics Incorporated

Inventor： Stacie Shepherd ,  Joseph K. Belanoff

IPC: A61K47/64 ,  A61K31/337 ,  A61K31/4745 ,  A61P15/00 ,  A61P35/00

CPC classification number: A61K47/643 ,  A61K31/337 ,  A61K31/4745 ,  A61P15/00 ,  A61P35/00 ,  A61K31/4745 ,  A61K2300/00 ,  A61K31/337 ,  A61K2300/00

Abstract: Methods and compositions for treating cancer (e.g., ovarian, fallopian tube, uterine, cervical, vaginal, vulvar, or peritoneal cancer) are disclosed. The methods include intermittent administration of a glucocorticoid receptor modulator (GRM), such as a non-steroidal GRM (e.g., relacorilant), which may be orally administered, along with a cancer chemotherapy agent (such as, e.g., bevacizumab) to the patient. The GRM may be administered: at intervals separated by at least one day without GRM administration; by a schedule linked to the cancer chemotherapy schedule (e.g., a weekly chemotherapy regimen); on the day of, or the day before, or the day after, chemotherapy administration; by combinations thereof; and/or on other days. Ovarian cancer patients receiving intermittent relacorilant administration along with nab-paclitaxel administration had improved overall survival, improved progression free survival, improved duration of response, and other benefits as compared to patients not receiving relacorilant while receiving nab-paclitaxel.

公开(公告)号：US12083227B2

公开(公告)日：2024-09-10

申请号：US16105440

申请日：2018-08-20

Applicant: AbbVie Inc. ,  Neurocrine Biosciences, Inc.

Inventor： Yihong Qiu ,  Yuchuan Gong ,  Alexander Ruggles ,  Jared A. Baird ,  Hui Zu ,  Gregory A. McClelland ,  Anna V. Stepanenko

IPC: A61K9/20 ,  A61K31/513 ,  A61P15/00

CPC classification number: A61K9/2031 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K31/513 ,  A61P15/00

Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

公开(公告)号：US20240216459A1

公开(公告)日：2024-07-04

申请号：US18397580

申请日：2023-12-27

Applicant: ACCESS BUSINESS GROUP INTERNATIONAL LLC

Inventor： Mary MURRAY ,  Gigi KWOK-HINSLEY ,  Yingqin LI ,  Gloria HSU ,  Arun RAJGOPAL

IPC: A61K36/53 ,  A23L2/395 ,  A61K9/00 ,  A61K36/8965 ,  A61P15/00

CPC classification number: A61K36/53 ,  A23L2/395 ,  A61K9/0053 ,  A61K9/0095 ,  A61K36/8965 ,  A61P15/00

Abstract: The described invention relates to a composition for preventing, treating, or relieving menstrual symptoms or discomforts and providing mood improvement in a female patient comprising: (i) an ingredient or an extract of chasteberry fruit; (ii) an ingredient or an extract of saffron red sargol stigma, wherein the ingredient or the extract of saffron red sargol stigma is encapsulated by maltodextrin; and (iii) an excipient. The described invention also relates to a method of using the composition for prevention and amelioration of common menstrual cycle symptoms and/or discomforts in female subjects.

公开(公告)号：US11987600B2

公开(公告)日：2024-05-21

申请号：US16444992

申请日：2019-06-18

Applicant: The Regents of the University of California

Inventor： Polina V. Lishko ,  Nadja Mannowetz

IPC: A61K31/56 ,  A61K9/00 ,  A61P15/00 ,  A61P15/18 ,  C07J53/00

CPC classification number: C07J53/002 ,  A61K9/00 ,  A61K9/0034 ,  A61K9/0036 ,  A61K31/56 ,  A61P15/00 ,  A61P15/18

Abstract: Disclosed are systemic and intravaginal non-hormonal contraceptives comprising a spermicidal triterpenoid. The contraceptive may be in the form of a foam, cream or gel, or in unit form of a pill, vaginal contraceptive film (VCF), suppository, sponge, transdermal or hypodermal patches or a slow release intravaginal device or intrauterine device such as a drug-impregnated silicone elastomer vaginal ring or polymeric IUD.

公开(公告)号：US20240150707A1

公开(公告)日：2024-05-09

申请号：US18412654

申请日：2024-01-15

Applicant: LACTOMASON CO., LTD.

Inventor： Minn SOHN ,  Tae Rahk KIM

IPC: C12N1/20 ,  A61K35/747 ,  A61P15/00 ,  C12R1/225

CPC classification number: C12N1/205 ,  A61K35/747 ,  A61P15/00 ,  C12R2001/225

Abstract: The present disclosure relates to a strain of Lactobacillus gasseri LM1065 (KCCM13018P) and a composition of relieving premenstrual syndrome containing the strain.
A strain of Lactobacillus gasseri LM1065 (KCCM13018P) according to an embodiment of the present disclosure can relieve premenstrual syndrome by reducing NO in blood and TL-6 gene expression and increasing the production ratio of prostaglandin E1/prostaglandin E2 in blood and DGLA levels. Therefore, the strain can be applied to food compositions, health functional food compositions, pharmaceutical compositions, and the like.

公开(公告)号：US20240076281A1

公开(公告)日：2024-03-07

申请号：US18070408

申请日：2022-11-28

Applicant: Arvinas Operations, Inc.

Inventor： Yimin QIAN ,  Hanqing DONG ,  Jing WANG

IPC: C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/519 ,  A61K31/5386 ,  A61K31/551 ,  A61K38/05 ,  A61K38/06 ,  A61K45/06 ,  A61K47/54 ,  A61P15/00 ,  A61P35/00 ,  C07D401/04 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D498/10 ,  C07K5/078 ,  C07K5/083

CPC classification number: C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/519 ,  A61K31/5386 ,  A61K31/551 ,  A61K38/05 ,  A61K38/06 ,  A61K45/06 ,  A61K47/54 ,  A61K47/545 ,  A61P15/00 ,  A61P35/00 ,  C07D401/04 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D498/10 ,  C07K5/06165 ,  C07K5/0806 ,  C07K5/06034

Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.